NCT06737419Completed
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
Source: ClinicalTrials.gov · Last updated 17 Dec 2024
Brief summary (registry, in English)
This was a retrospective cohort study using the electronic medical record (EMR) database from Cleveland Clinic. The data was analyzed at start of ofatumumab (OMB) therapy (baseline, defined as 6 months prior to OMB initiation) and at 6 or 12 months following initiation of OMB.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 175 (actual)
- First submitted
- 12 Dec 2024
- Start date
- 9 Jun 2021
- Primary completion date
- 5 Feb 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Multiple sclerosis
- NCT number
- NCT06737419
What you commit to
- Study type: Observational
- Participants enrolled: 175
- From 9 Jun 2021 to the primary completion date, 5 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients who initiated OMB commercially from the time of disease modifying therapy (DMT) approval (August 2020), and
- Aged 18 years or older at index date, and
- Patients who met 2017 McDonald Criteria for clinically definite multiple sclerosis (MS), or
- Patients diagnosed with clinically isolated syndrome (CIS) by Cleveland Clinic MS specialist.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.